Early clinical signals (e.g., IL-1/IL-6 pathway agents in New Onset Refractory Status Epilepticus (NORSE)/febrile infection-related epilepsy syndrome (FIRES)) and robust preclinical data support continued translational work [2,5]. Here, IL6 is linked to new-onset refractory status epilepticus.